For over 20 years, Marc Recht has represented life sciences and other healthcare companies and investors in public and private transactions, including securities offerings, joint ventures and M&A matters. He also has extensive experience advising public companies boards of directors and management teams regarding Securities and Exchange Commission periodic disclosure, Sarbanes-Oxley compliance, corporate governance and Nasdaq and New York Stock Exchange rules.

Download full bio 


  • Exscientia – $510.4 Million IPO 

  • Exscientia Inks Investment of up to $525 Million 

  • Talaris Therapeutics – $150 Million IPO 

  • Celularity to Go Public Through SPAC Merger 

  • Oncorus – $98 Million IPO 

  • View all

Excellent in all categories. Marc Recht is 'very technically skilled in corporate matters and plays a strong quarterback role.' – Legal 500

  • Boston College Law School
    JD, magna cum laude, 1999

  • Brandeis University
    BA, with honors, 1995

Admissions & Credentials


Rankings & Accolades

    Chambers USA: Capital Markets –Massachusetts (2014-2022)

    The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)

    Who's Who Legal: Life Sciences (2017, 2018)

    Super Lawyers: Rising Star (2007, 2010 – 2013)

    Boston Business Journal: Biotech IPO (2015)